<DOC>
	<DOCNO>NCT00663884</DOCNO>
	<brief_summary>We evaluate efficacy safety combination therapy 10 mg mitiglinide 0.2mg voglibose insulin glargine 16 week single administration insulin glargine 4 week type 2 diabetic patient whose glycemic control enough despite administration oral antidiabetic drug insulin glargine .</brief_summary>
	<brief_title>Glufast On Insulin Glargine Trial Type 2 DM</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Voglibose</mesh_term>
	<mesh_term>Mitiglinide</mesh_term>
	<mesh_term>Inositol</mesh_term>
	<criteria>The type 2 diabetic patient age 30 70 The patient whose Hb1Ac 7.0 % despite administration two oral antidiabetic drug 6 month insulin glargine 3 month registration Outpatients whose BMI 21 40 kg/㎡ The patient consent participate clinical study write The patient use insulin formulation except insulin glargine The patient whose fast blood glucose 270 mg/dL The patient whose Cpeptide 1ng/ml empty stomach The patient surgically operate gastrointestinal tract The patient need additional treatment underwent operation within 3 month severe complication diabetic foot ulcer , retinopathy neuropathy The patient severe hepatic dysfunction : uncompensated hepatic cirrhosis , case aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) 2.5 time higher normal limit ( ≥ 2.5 x normal range ) The patient unstable angina acute myocardial infarction occur within 3months The patient renal failure severe hypertension : diastolic blood pressure 110mmHg despite drug treatment The patient lifethreatening disease cancer severe infection The patient history drug allergy Pregnant breast feed woman likely pregnant The patient need oral parenteral corticosteroid The patient judge unsuitable clinical study reason</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>diabetes mellitus , Type 2</keyword>
	<keyword>mitiglinide</keyword>
</DOC>